Genetic determinants of drug responsiveness and drug interactions

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 517-524

  Caraco, Yoseph ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cytochrome P450; Drug interactions; Interindividual variability; Pharmacogenetics

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOMIPRAMINE; CODEINE; CYTOCHROME P450; DESIPRAMINE; DEXTROMETHORPHAN; ENCAINIDE; FLECAINIDE; IMMUNOSUPPRESSIVE AGENT; METOPROLOL; MEXILETINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; PERPHENAZINE; PRAJMALINE; PROPAFENONE; PROPRANOLOL; PROTON PUMP INHIBITOR; SEDATIVE AGENT; SPARTEINE; TIMOLOL; TRAMADOL; UNINDEXED DRUG;

ALLELE; CONFERENCE PAPER; DRUG INTOXICATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC VARIABILITY; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL;

EID: 0031658353     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00012     Document Type: Conference Paper

References (48)

1. Kalow W, Genset K. A method for the detection of atypical forms of human serum cholinesterase: determination of dibucaine numbers. Can J Biochem 1957;35:339-46.
2. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964;14:542-8.
3. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;i:584-6.
4. Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a resistant subject. Br J Clin Pharmacol 1993;35: 327-30.
5. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-80.
6. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
7. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996;24:449-59.
8. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997;37:40S-48S.
9. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994;46(suppl):417-24.
10. Siddoway LA, Thompson KA, McAllister B, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
11. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive ?-blockade following timolol eye drops, potential for oralophthalmic drug interaction. JAMA 1995;274:1611-3.
12. Lennard MS, Silas JH, Freestone S, Ramsay BL, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Eng J Med 1982;307:1558-60.
13. Bertilsson L, Mellstrom B, Sjoqvist F, Martensson B, Asberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1981;i:560-1.
14. Meyer JW, Woggon B, Kupfer A. Importance of oxidative polymorphism on clinical efficacy and side effects of imipramine - a retrospective study. Pharmacopsychiatry 1988;21:365-6.
15. Caraco Y, Sheller JR, Wood AJJ. Pharmacogenetic determinants of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996;278:1165-1174.
16. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1991;49:686-93.
17. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-44.
18. Shah RR, Oates NS, Idle JR, Smith RL Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982:295-9.
19. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983;34:827-34.
20. Chang M, Tybring G, Dahl ML, et al. Interphenotypic differences in disposition and effect on gastrin of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39:511-8.
21. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole's disposition and effect. Clin Pharmacol Ther 1996;60:157-67.
22. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
23. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-90.
24. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM. Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-8.
25. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
26. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo, Clin Pharmacol Ther 1995;58:556-66.
27. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
28. Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-8.
29. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60: 522-34.
30. Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I. Pheno-typing of CYP2C19 with enantiospecific HPLC-quantification of R and S-mephenytoin and comparison with intron4/exon5 G to A site mutation. Pharmacogenetics 1995;5:80-8.
31. Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate oCYP2C19) and comparison with two mutant alleles. CYP2C19m1 in exon 5 and CYP2C19m2 in exon4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
32. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic-analysis of CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
33. Sterward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-7.
34. Hashimoto Y, Otsuki Y, Odani A, et al. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull 1996;19:1103-5.
35. Furuya H, Fernandez-Salguero PW, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5:389-92.
36. Guengerich FP. In vivo techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996;24:521-32
37. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a toll for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321-32.
38. Atiba JO, Blaschke TF, Wilkinson GR. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol 1989;28:161-5.
39. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine,fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
40. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
41. Caraco Y, Wilkinson G, Wood AJJ. Differences between Caucasians and Chinese in the in vivo inhibition of cytochrome P450s 2C19, 2D6 and 3A4 by omeprazole. Clin Pharmacol Ther 1996; 60:396-404.
42. Inaba T, Tyndale RE, Mahon WA. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol 1986;22:194-7.
43. Anonymous. Roche, FDA announce new drug-interaction warnings for mibefradil. Am J Health Syst Pharm 1998;55:210.
44. Schellens JH, Ghabrial H, van der Wart HHF, Bakker EN, Wilkinson GR, Breimer DD. Differential effect of quinidine on the disposition of nifedipine, sparteine and mephenytoin in humans. Clin Pharmacol Ther 1991;50:520-8.
45. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987;24:543-5.
46. Steiner E, Iselius L, Alvan G, Linsten J, Sjoqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985;38:394-401.
47. Caraco Y, Sheller JR, Wood AJJ. Pharmacogenetic determinants of codeine induction by rifampicin: the impact on codeine's respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther 1997;281:330-6.
48. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the b2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-8.